Silk Road Medical Inc (SILK)
Company Description
Silk Road Medical, Inc. operates as a medical device company in the United States.
The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization.
Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.
The company was incorporated in 2007 and is headquartered in Sunnyvale, California.

Country | United States |
IPO Date | Apr 4, 2019 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 474 |
CEO | Charles S. McKhann |
Contact Details
Address: 1213 Innsbruck Drive Sunnyvale, California United States | |
Website | https://silkroadmed.com |
Stock Details
Ticker Symbol | SILK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001397702 |
CUSIP Number | 82710M100 |
ISIN Number | US82710M1009 |
Employer ID | 20-8777622 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Charles S. McKhann | Chief Executive Officer & Director |
Kevin M. Klemz | Executive Vice President, Chief Legal Officer & Secretary |
Lucas W. Buchanan | Chief Financial Officer & Chief Operating Officer |
Alison Highlander | Vice President of Human Resources |
Andrew S. Davis | Chief Commercial Officer |
Erica J. Rogers | Independent Consultant |
Jorge O'Hara | Vice President of Marketing, Business Development & Strategy |
Mhairi L. Jones | Chief Accounting Officer & Vice President of Finance |
Richard M. Ruedy | Executive Vice President of Clinical, Regulatory Affairs & Quality Assurance |
Tammy Leitsinger | Compliance Officer & Vice President of Medical Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 05, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Sep 27, 2024 | 15-12G | Filing |
Sep 19, 2024 | SC 13D/A | [Amend] Filing |
Sep 18, 2024 | 4 | Filing |
Sep 18, 2024 | 4 | Filing |
Sep 18, 2024 | 4 | Filing |
Sep 18, 2024 | 4 | Filing |
Sep 18, 2024 | 4 | Filing |
Sep 18, 2024 | 4 | Filing |
Sep 18, 2024 | 4 | Filing |